| Title: |
Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study |
| Authors: |
Oliva, Fabrizio; Orso, Francesco; Colivicchi, Furio; Cipriani, Manlio Gianni; Di Lenarda, Andrea; Gori, Mauro; Gorini, Marco; Iacoviello, Massimo; Lucci, Donata; Marini, Marco; Bonvicini, Eleonora; Carugo, Stefano; Catalano, Mariarosaria; D’Elia, Emilia; Gentile, Piero; Matassini, Maria Vittoria; Navazio, Alessandro; Russo, Domitilla; Tini, Giacomo; Tinti, Maria Denitza; Grimaldi, Massimo; Gabrielli, Domenico; Maggioni, Aldo Pietro; Maggioni, Aldo P; Gonzini, Lucio; Bianchini, Francesca; Baldini, Ester; Cangioli, Ilaria; De Ferrari, Gaetano Maria; Raineri, Claudia; Frea, Simone; Giammaria, Massimo; Biolè, Carloalberto; Nangeroni, Giulia; Moretti, Claudio; Franco, Erica; Capriolo, Michele; Gaiero, Lorenzo |
| Contributors: |
Heart Care Foundation; Boehringer-Ingelheim Italia; Eli-Lilly Italia; Novartis Farma SpA; Vifor Pharma Italia |
| Source: |
ESC Heart Failure ; volume 13, issue 2 ; ISSN 2055-5822 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2026 |
| Description: |
Introduction The BRING-UP 3 Heart Failure (HF) study was designed to evaluate the real-world implementation of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), given the limited evidence on the uptake of the contemporary four-pillar treatment strategy. Methods BRING-UP 3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites. This analysis includes HFrEF patients enrolled in the ambulatory and hospitalized cohorts with complete pharmacological data at 6-month follow-up. The objective was to describe the use of the four GDMT pillars after 6 months. Results Among 3201 HFrEF patients enrolled, 142 (4.4%) had died by 6 months, and treatment data were available for 2950 patients. Mean age was 69 ± 11 years (26.6% > 75 years), 18.0% were female. Prescription rates of GDMT were high at baseline and remained stable over 6-months, with a shift from ACE-I/ARBs to ARNIs, and a modest increase in SGLT2i use. A significant reduction in diuretic prescription was also observed. Quadruple therapy was prescribed in 64.3% of patients at 6 months versus 63.9% at baseline/discharge (P = NS), while quadruple therapy including ARNI went from 52.9% to 55.9%, P < .0001. Dose up-titration of GDMT remained suboptimal, with most agents prescribed at |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/eschf/xvag043 |
| DOI: |
10.1093/eschf/xvag043/66661933/xvag043.pdf |
| Availability: |
https://doi.org/10.1093/eschf/xvag043; https://academic.oup.com/eschf/advance-article-pdf/doi/10.1093/eschf/xvag043/66661933/xvag043.pdf; https://academic.oup.com/eschf/article-pdf/13/2/xvag043/66661933/xvag043.pdf |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.6ED6A3CC |
| Database: |
BASE |